World’s 1st iPS-Derived Medicine to Treat Parkinson’s Disease Approved for Coverage under Public Insurance Scheme
Japan’s Central Social Insurance Medical Council approved Amchepry, the world’s first induced pluripotent stem cell-derived medicine for Parkinson’s disease, for public insurance coverage on May 13, 2026. Developed by Sumitomo Pharma, the treatment costs approximately 55 million yen per dose and targets patients unresponsive to conventional therapies.
Japan’s Central Social Insurance Medical Council approved coverage for Amchepry, the world’s first induced pluripotent stem cell (iPS)-derived medicine for Parkinson’s disease, on May 13, 2026. The decision marks the first practical application of iPS cell-derived therapy globally, with the government setting the price at around 55 million yen per dose. Developed by Sumitomo Pharma Co., Amchepry involves transplanting nerve cells derived from iPS cells into patients’ brains. The treatment is specifically intended for Parkinson’s patients who have not responded adequately to existing medications. The approval follows years of research and regulatory review, positioning Japan as a leader in regenerative medicine. The therapy represents a breakthrough for patients with advanced Parkinson’s disease, offering a potential alternative to conventional treatments. The Central Social Insurance Medical Council, an advisory panel to Japan’s Health, Labor and Welfare minister, recommended the coverage after evaluating safety and efficacy data. This decision paves the way for broader access to iPS-based therapies in the country. While the treatment is groundbreaking, its high cost and technical complexity may present challenges for widespread adoption. However, the approval sets a precedent for future stem cell therapies in Japan and beyond.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.